荷兰各医院乳腺癌乳房切除后即刻乳房再造率差异显著
该研究基于荷兰NABON乳腺癌审计数据,纳入2011至2013年因原发性浸润性乳腺癌或导管原位癌(DCIS)行乳房切除术的患者,比较全国92家医院的即刻乳房再造(IBR)使用率。未调整分析显示医院间IBR率差异很大,浸润性癌均值17%(范围0-64%)、DCIS均值42%(范围0-83%);按患者与肿瘤因素进行病例组合调整后差异仍大(浸润性癌0-43%、DCIS 0-74%)。
要点
- 荷兰92家医院乳房切除后IBR率差异大,浸润性癌0-64%、DCIS 0-83%
- 年轻、多灶病变等因素与更高IBR率相关
- 病例组合调整后医院间IBR率差异仍然明显
核心结论
- 荷兰医院间乳房切除后即刻乳房再造率存在大幅差异,且不能由患者和肿瘤因素解释。
研究设计与样本
- 共纳入荷兰全部92家医院,总计16,953例乳房切除术,其中浸润性乳腺癌15,072例、DCIS 1,881例。
主要发现
- 未调整分析中,浸润性乳腺癌乳房切除后IBR率均值17%(范围0-64%),DCIS均值42%(范围0-83%)。
- DCIS中,年轻年龄和多灶病变显著提高IBR率。
- 浸润性乳腺癌中,年轻、多灶肿瘤、较小肿瘤、较低分级、无淋巴结受累、导管癌或激素受体阳性/HER2阳性肿瘤更常使用IBR。
- 病例组合调整后医院间IBR使用差异仍大,浸润性乳腺癌0-43%、DCIS 0-74%。
临床怎么用
- 提示应关注医院层面再造服务可及性与决策差异,推动符合指征患者获得一致的再造咨询与选择。
局限性
- 为审计登记数据的回顾性分析,未报告各医院具体再造方式、患者偏好及术者因素等信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The present study aimed to describe the use of immediate breast reconstruction (IBR) after mastectomy for invasive breast cancer and ductal carcinoma in situ (DCIS) in hospitals in the Netherlands and determine whether patient and tumor factors account for the variation. METHODS: Patients undergoing mastectomy for primary invasive breast cancer or DCIS diagnosed between January 1, 2011 and December 31, 2013 were selected from the NABON Breast Cancer Audit. All the 92 hospitals in the Netherlands were included. The use of IBR in all hospitals was compared using unadjusted and adjusted analyses. Patient and tumor factors were evaluated by univariate and multivariate analyses. RESULTS: In total, 16,953 patients underwent mastectomy: 15,072 for invasive breast cancer and 1881 for DCIS. Unadjusted analyses revealed considerable variation between hospitals in postmastectomy IBR rates for invasive breast cancer (mean 17%; range 0-64%) and DCIS (mean 42%; range 0-83%). For DCIS, younger age and multifocal disease were factors that significantly increased IBR rates. For patients diagnosed with invasive breast cancer, IBR was more often used in younger patients, multifocal tumors, smaller tumors, tumors with a lower grade, absence of lymph node involvement, ductal carcinomas, or hormone-receptor positive/HER2-positive tumors. After case-mix adjustments for these factors, the variation in the use of IBR between hospitals remained large (0-43% for invasive breast cancer and 0-74% for DCIS). CONCLUSIONS: A large variation between hospitals was found in postmastectomy IBR rates in the Netherlands for both invasive breast cancer and DCIS even after adjustment for patient and tumor factors.
引用
- van Bommel AC, Mureau MA, Schreuder K, et al. Large variation between hospitals in immediate breast reconstruction rates after mastectomy for breast cancer in the Netherlands. J Plast Reconstr Aesthet Surg. 2016. PMID: 27993547. doi:10.1016/j.bjps.2016.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。